BACKGROUND: CC Chemokine receptor 4 (CCR4) is preferentially expressed on Th2 lymphocytes. CCR4-mediated inflammation may be important in the pathology of allergic rhinitis. Disruption of CCR4 - ligand interaction may abrogate allergen-induced inflammation. METHODS: Sixteen allergic rhinitics and six nonatopic individuals underwent both allergen and control (diluent) nasal challenges. Symptom scores and peak nasal inspiratory flow were recorded. Nasal biopsies were taken at 8 h post challenge. Sections were immunostained and examined by light or dual immunofluorescence microscopy for eosinophils, T-lymphocytes, CCR4(+)CD3(+) and CXCR3(+)CD3(+) cells and examined by in situ hybridization for CCR4, IL-4 and IFN-gamma mRNA(+) cells. Peripheral blood mononuclear cells were obtained from peripheral blood of nine normal donors and the CCR4(+)CD4(+) cells assessed for actin polymerization in response to the CCR4 ligand macrophage-derived chemokine (MDC/CCL22) and the influence of a CCR4 antagonist tested. RESULTS:Allergic rhinitics had increased early and late phase symptoms after allergen challenge compared to diluent; nonatopics did not respond to either challenge. Eosinophils, but not total numbers of CD3(+) T cells, were increased in rhinitics following allergen challenge. In rhinitics, there was an increase in CCR4(+)CD3(+) protein-positive cells relative to CXCR3(+)CD3(+) cells; CCR4 mRNA+ cells were increased and IL-4 increased to a greater extent than IFN-gamma. CCR4(+)CD4(+) T cells responded to MDC in vitro, and this response was inhibited by the selective CCR4 antagonist. CONCLUSION:Lymphocyte CCR4 expression is closely associated with induction of human allergen-induced late nasal responses. Blocking CCR4-ligand interaction may provide a novel therapeutic approach in allergic disease.
RCT Entities:
BACKGROUND:CC Chemokine receptor 4 (CCR4) is preferentially expressed on Th2 lymphocytes. CCR4-mediated inflammation may be important in the pathology of allergic rhinitis. Disruption of CCR4 - ligand interaction may abrogate allergen-induced inflammation. METHODS: Sixteen allergic rhinitics and six nonatopic individuals underwent both allergen and control (diluent) nasal challenges. Symptom scores and peak nasal inspiratory flow were recorded. Nasal biopsies were taken at 8 h post challenge. Sections were immunostained and examined by light or dual immunofluorescence microscopy for eosinophils, T-lymphocytes, CCR4(+)CD3(+) and CXCR3(+)CD3(+) cells and examined by in situ hybridization for CCR4, IL-4 and IFN-gamma mRNA(+) cells. Peripheral blood mononuclear cells were obtained from peripheral blood of nine normal donors and the CCR4(+)CD4(+) cells assessed for actin polymerization in response to the CCR4 ligand macrophage-derived chemokine (MDC/CCL22) and the influence of a CCR4 antagonist tested. RESULTS: Allergic rhinitics had increased early and late phase symptoms after allergen challenge compared to diluent; nonatopics did not respond to either challenge. Eosinophils, but not total numbers of CD3(+) T cells, were increased in rhinitics following allergen challenge. In rhinitics, there was an increase in CCR4(+)CD3(+) protein-positive cells relative to CXCR3(+)CD3(+) cells; CCR4 mRNA+ cells were increased and IL-4 increased to a greater extent than IFN-gamma. CCR4(+)CD4(+) T cells responded to MDC in vitro, and this response was inhibited by the selective CCR4 antagonist. CONCLUSION: Lymphocyte CCR4 expression is closely associated with induction of human allergen-induced late nasal responses. Blocking CCR4-ligand interaction may provide a novel therapeutic approach in allergic disease.
Authors: E M Minshall; L Cameron; F Lavigne; D Y Leung; D Hamilos; E A Garcia-Zepada; M Rothenberg; A D Luster; Q Hamid Journal: Am J Respir Cell Mol Biol Date: 1997-12 Impact factor: 6.914
Authors: E D Bateman; S S Hurd; P J Barnes; J Bousquet; J M Drazen; J M FitzGerald; P Gibson; K Ohta; P O'Byrne; S E Pedersen; E Pizzichini; S D Sullivan; S E Wenzel; H J Zar Journal: Eur Respir J Date: 2008-01 Impact factor: 16.671
Authors: R Bonecchi; G Bianchi; P P Bordignon; D D'Ambrosio; R Lang; A Borsatti; S Sozzani; P Allavena; P A Gray; A Mantovani; F Sinigaglia Journal: J Exp Med Date: 1998-01-05 Impact factor: 14.307
Authors: E Danilova; I Skrindo; E Gran; B J Hales; W A Smith; J Jahnsen; F E Johansen; F L Jahnsen; E S Baekkevold Journal: Mucosal Immunol Date: 2014-06-11 Impact factor: 7.313
Authors: A Jafarzadeh; H A Ebrahimi; S Bagherzadeh; F Zarkesh; F Iranmanesh; A Najafzadeh; A Khosravimashizi; M Nemati; A Sabahi; H Hajghani; H Daneshvar; M M Mohammadi Journal: Inflammation Date: 2014-04 Impact factor: 4.092
Authors: Jonathan M Viney; David P Andrew; Rhian M Phillips; Andrea Meiser; Pallavi Patel; Melissa Lennartz-Walker; David J Cousins; Nicholas P Barton; David A Hall; James E Pease Journal: J Immunol Date: 2014-02-21 Impact factor: 5.422
Authors: Anthony Cahn; Simon Hodgson; Robert Wilson; Jonathan Robertson; Joanna Watson; Misba Beerahee; Steve C Hughes; Graeme Young; Rebecca Graves; David Hall; Sjoerd van Marle; Roberto Solari Journal: BMC Pharmacol Toxicol Date: 2013-02-28 Impact factor: 2.483
Authors: J Galicia-Carreón; C Santacruz; J Ayala-Balboa; A Robles-Contreras; S M Perez-Tapia; Y Garfias; E Hong; M C Jiménez-Martínez Journal: Clin Dev Immunol Date: 2013-12-04